All In Biotech

Free tool

FAERS Monitor: Ibsrela

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211801 or its brand name (Ibsrela, Tenapanor Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

3,714

Serious

1,104

30% of reports

Hospitalization

627

Death reported

114

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea1,288
  • product use issue444
  • inappropriate schedule of product administration401
  • therapy interrupted294
  • product use in unapproved indication261
  • abdominal distension247
  • drug ineffective219
  • off label use209
  • insurance issue208
  • intentional underdose179
  • abdominal pain upper167
  • abdominal pain148
  • nausea147
  • flatulence135
  • underdose125

Reports by year received

View as table
YearReports
20161
20171
20192
20202
20211
202242
2023103
2024353
2025500
20262,709

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,445 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional underdoseSignal179142.2123.124,359
insurance issueSignal20878.168.415,547
therapy interruptedSignal29423.421.06,274
flatulenceSignal13513.511.41,552
abdominal distensionSignal24713.411.92,836
product use issueSignal44413.412.35,120
inappropriate schedule of product administrationSignal40112.611.54,309
diarrhoeaSignal1,28811.310.812,467
underdoseSignal1259.78.2970
product use in unapproved indicationSignal2616.05.31,086
abdominal pain upperSignal1674.64.0471
abdominal painSignal1483.63.1279
off label use2091.41.220
nausea1471.10.90
drug ineffective2190.90.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.